BridgeMD
Exploring the Psychoactive Effects of Paracetamol: A Randomized Controlled Trial.
EU CTIS ID: 2025-522753-19-02
What this study is testing
Primary objective: to assess whether paracetamol can reduce negative affective experiences compared to placebo over 7 days of treatment.
- Therapeutic use (Phase IV)
A plain-language read of the study's public EU CTIS listing. The study team confirms the details.
Who can take part
You may be able to join if
- Age: 18-30
- Participants who are overtly healthy as determined by self-report and blood tests
- Weight: Body weight within 45 – 120 kg and Body Mass Index within the range 18.5 – 30 kg/m2
- Contraceptives: Contraceptive use by women should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies.
- Informed Consent: Capable of giving signed informed consent as described in Appendix 1. which includes compliance with the requirements and restrictions listed in the informed consent form (ICF) and in this protocol.
- Language: Able to communicate fluently in Norwegian, as this will be the language in which study material, including the ICF is written in.
You likely can't join if
- Allergic to paracetamol or any of the other ingredients of this medicine (listed in section 6, package insert).
- Chronic pain condition
- Currently being evaluated for, or undergoing treatment for medical/physical, psychological condition(s) or neuropsychiatric diagnoses
- Acute inflammation of the liver (hepatitis)
- Previous or current liver injury or kidney injury
- Pregnancy
See the full eligibility criteria
- Age: 18-30
- Participants who are overtly healthy as determined by self-report and blood tests
- Weight: Body weight within 45 – 120 kg and Body Mass Index within the range 18.5 – 30 kg/m2
- Contraceptives: Contraceptive use by women should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies.
- Informed Consent: Capable of giving signed informed consent as described in Appendix 1. which includes compliance with the requirements and restrictions listed in the informed consent form (ICF) and in this protocol.
- Language: Able to communicate fluently in Norwegian, as this will be the language in which study material, including the ICF is written in.
- Allergic to paracetamol or any of the other ingredients of this medicine (listed in section 6, package insert).
- Chronic pain condition
- Currently being evaluated for, or undergoing treatment for medical/physical, psychological condition(s) or neuropsychiatric diagnoses
- Acute inflammation of the liver (hepatitis)
- Previous or current liver injury or kidney injury
- Pregnancy
- BMI ≤18.5 kg/m2 or BMI>30
The study team makes the final eligibility decision.
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18-64 years. The study team makes the final eligibility decision.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from EU CTIS; the study team decides eligibility.